Physician profile
Anil Nanda
NPI 1568461192
$34,667.04
in general payments reported to CMS, 2019-2025
29 companies · $9,353 in 2025
The $9,353 reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $169 · 2021: $6,543 · 2022: $2,374 · 2023: $11K · 2024: $3,727 · 2025: $9,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $6,260 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,395 · Travel and Lodging: $1,031 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,827.50 |
| Food and Beverage | $6,260.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,395.00 |
| Travel and Lodging | $1,030.59 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,222.67 | 2019-2025 | |
| Genzyme Corporation | $5,486.02 | 2020-2025 | |
| Glaxosmithkline, LLC. | $5,246.26 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Pfizer INC. | $5,198.77 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,846.44 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Aquestive Therapeutics, INC. | $2,254.22 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $2,136.54 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $559.37 | 2019-2025 | Xolair |
| Alk-Abello, INC | $479.26 | 2019-2023 | Odactra, Grastek, Ragwitek |
| Pharming Healthcare, INC. | $259.87 | 2024-2025 | Joenja |
| Takeda Pharmaceuticals U.S.A., INC. | $216.07 | 2021-2025 | Cuvitru, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.42 | 2019 | |
| Adma Biomanufacturing LLC | $160.13 | 2022 | |
| Galderma Laboratories, L.P. | $153.98 | 2024 | |
| Amgen INC. | $151.80 | 2022-2025 | Tezspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $139.20 | 2025 | Neffy |
| Blueprint Medicines Corporation | $134.75 | 2023-2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $125.04 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $123.05 | 2022 | |
| Lilly USA, LLC | $110.13 | 2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $110.00 | 2021 | |
| Optinose US, INC. | $104.32 | 2022 | |
| Incyte Corporation | $93.78 | 2023 | Opzelura |
| Mimedx Group, INC. | $41.58 | 2025 | |
| Phadia US INC. | $33.06 | 2020 | |
| Genentech, INC. | $30.01 | 2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $20.79 | 2021 | |
| Merck Sharp & Dohme LLC | $16.51 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.